Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Asterand Launches GLP Pathology Services | Contract Pharma

What are you searching for?

Sign in
Breaking News

Asterand Launches GLP Pathology Services

Asterand adds to PhaseZERO suite of preclinical services

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Asterand plc has launched GLP-compliant molecular pathology services supporting preclinical safety studies. The company’s first new service offering will be tissue cross reactivity testing for therapeutic antibodies in order to supply clients with critical data required by regulatory authorities for IND submissions.

Acceptance as a member of the UK GLP Compliance Monitoring Programme will also allow Asterand to expand its offering of GLP-compliant preclinical services to its pharmaceutical and biotech clients.

Dr. Tony Brown, Asterand’s general manager, UK Operations, commented, “We are extremely pleased to add GLP-compliant tissue cross reactivity studies to our growing suite of PhaseZERO® services. These services will meet a critical need within a new market for Asterand. Our key customers are the world’s top 30 pharmaceutical companies, who increasingly look to source a broader range of services from external providers. This acceptance into the UK GLP Monitoring Compliance Programme allows us to broaden our service offering and provide more opportunities for our customers to develop ‘one-stop shop’ partnerships with Asterand.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters